H.C. Wainwright downgraded Clearside Biomedical (CLSD) to Neutral from Buy without a price target after the company said it is exploring strategic alternatives. No agreement for any strategic transaction has been reached and no timetable has been set for the strategic review process, the analyst tells investors in a research note.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CLSD:
- Clearside Biomedical downgraded to Neutral from Buy at Chardan
- Clearside Biomedical downgraded to Hold from Buy at Stifel
- Clearside Biomedical Downgraded to Hold Amid Strategic and Financial Uncertainties
- Needham downgrades Clearside on ‘disappointing’ decision to explore options
- Clearside Biomedical downgraded to Hold from Buy at Needham